Among the allosteric inhibitors (Figure 1), MK-2206 has been evaluated as monotherapy in the phase II trial NCT01277757 in patients with advanced breast cancer and tumors harboring PIK3CA or Akt mutations and/or PTEN loss or mutations. Here, AKT1 is linked to breast cancer.